These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 2883012

  • 21. A study of the mechanism of MDMA ('ecstasy')-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds.
    Colado MI, Green AR.
    Br J Pharmacol; 1994 Jan; 111(1):131-6. PubMed ID: 7516800
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems.
    Johnson M, Elayan I, Hanson GR, Foltz RL, Gibb JW, Lim HK.
    J Pharmacol Exp Ther; 1992 May; 261(2):447-53. PubMed ID: 1349640
    [Abstract] [Full Text] [Related]

  • 27. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats.
    Koprich JB, Chen EY, Kanaan NM, Campbell NG, Kordower JH, Lipton JW.
    Neurotoxicol Teratol; 2003 May; 25(5):509-17. PubMed ID: 12972064
    [Abstract] [Full Text] [Related]

  • 28. Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat.
    Hekmatpanah CR, McKenna DJ, Peroutka SJ.
    Neurosci Lett; 1989 Sep 25; 104(1-2):178-82. PubMed ID: 2573011
    [Abstract] [Full Text] [Related]

  • 29. Regional distribution to recovery of 5-HT levels after administration of "atrophins" MDMA and D,L-fenfluramine. Stereospecificity and comparison with 5,7-dihydroxytryptamine.
    Lehmann J, DeSouza EB, Culp S, Zaczek R.
    Ann N Y Acad Sci; 1992 May 11; 648():291-5. PubMed ID: 1379013
    [No Abstract] [Full Text] [Related]

  • 30. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain.
    Steele TD, Nichols DE, Yim GK.
    Biochem Pharmacol; 1987 Jul 15; 36(14):2297-303. PubMed ID: 2886126
    [Abstract] [Full Text] [Related]

  • 31. Characterization of acute N-ethyl-3,4-methylenedioxyamphetamine (MDE) action on the central serotonergic system.
    Johnson M, Hanson GR, Gibb JW.
    Biochem Pharmacol; 1989 Dec 01; 38(23):4333-8. PubMed ID: 2480796
    [Abstract] [Full Text] [Related]

  • 32. Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog.
    Johnson M, Hanson GR, Gibb JW.
    Eur J Pharmacol; 1989 Jun 20; 165(2-3):315-8. PubMed ID: 2570704
    [Abstract] [Full Text] [Related]

  • 33. Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration.
    Johnson MP, Nichols DE.
    Pharmacol Biochem Behav; 1989 May 20; 33(1):105-8. PubMed ID: 2476831
    [Abstract] [Full Text] [Related]

  • 34. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
    Colado MI, Williams JL, Green AR.
    Br J Pharmacol; 1995 Aug 20; 115(7):1281-9. PubMed ID: 7582557
    [Abstract] [Full Text] [Related]

  • 35. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates.
    Ricaurte GA, Forno LS, Wilson MA, DeLanney LE, Irwin I, Molliver ME, Langston JW.
    JAMA; 1988 Jul 01; 260(1):51-5. PubMed ID: 2454332
    [Abstract] [Full Text] [Related]

  • 36. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain.
    Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS.
    J Pharmacol Exp Ther; 1987 Apr 01; 241(1):338-45. PubMed ID: 2883295
    [Abstract] [Full Text] [Related]

  • 37. 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates.
    Ricaurte GA, DeLanney LE, Wiener SG, Irwin I, Langston JW.
    Brain Res; 1988 Dec 06; 474(2):359-63. PubMed ID: 2463059
    [Abstract] [Full Text] [Related]

  • 38. Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity.
    Logan BJ, Laverty R, Sanderson WD, Yee YB.
    Eur J Pharmacol; 1988 Aug 02; 152(3):227-34. PubMed ID: 2906000
    [Abstract] [Full Text] [Related]

  • 39. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity.
    O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME.
    J Neurosci; 1988 Aug 02; 8(8):2788-803. PubMed ID: 2457659
    [Abstract] [Full Text] [Related]

  • 40. 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine.
    McKenna DJ, Guan XM, Shulgin AT.
    Pharmacol Biochem Behav; 1991 Mar 02; 38(3):505-12. PubMed ID: 1829838
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.